19 May 2013
Keywords: fda, backs, merck, co, emend, before, panel
Article | 10 March 2003
The US Food and Drug Administration has issued a memo in which itsupports the view that Merck & Co's Emend (aprepitant) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 March 2003
17 May 2013
© 2013 thepharmaletter.com